Genzyme Awarded Summary Judgment in Ala. Federal Knee Pain Device Case
March 16, 2021
DOCUMENTS
- Order
BIRMINGHAM, Ala. — An Alabama federal judge has awarded Genzyme Corp. summary judgment in an action concerning its knee pain medical device, ruling that the plaintiff has failed to establish medical causation and that his claims are preempted by federal law.
In two March 9 orders, Judge R. David Proctor of the U.S. District Court for the Northern District of Alabama concluded that the plaintiff has not pointed to any Rule 56 evidence that the contaminated Synvisc-One injection caused him to develop septic arthritis.
Ralph Lowery received an injection of Genzyme’s Synvisc-One, a Class III medical device, to relieve pain …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference
January 10, 2025 - Long Beach, CA
The Westin Long Beach